Citi downgraded SanBio to Sell from Neutral with a price target of 1,100 yen, up from 500 yen, following the announcement of conditional regulatory approval for Akuugo. The firm now assumes that Akuugo will begin shipping in Feb-Apr 2025, previously 2026, following resolution of manufacturing issues. Citi assumes peak annual sales of 36B yen, as the requirement that all cases be surveyed for the time being limits the number of medical institutions that can use the drug and SanBio’s sales capabilities are also limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNBIF: